ECE2015 Eposter Presentations Diabetes (complications & therapy) (143 abstracts)
Evaluating analogue vs human insulin efficacy in real life: observational study in type 2 Albanian diabetic patients, previously insulin treated
Florian Toti 1, , Gjinal Gjonçaj 1 , Blerina Resulaj 2 , Luftime Bruka 1 , Adriana Lapardhaja 1 , Manjola Carçani 1 , Rajmonda Tare 1 & Varvara Lile 1
1University Hospital Center ‘Mother Theresa’, Tirana, Albania; 2Faculty of Medicine, Tirana, Albania.
Background and aims: Insulin therapy is an important part of diabetes treatment. A lot of studies have compared the efficacy of new insulin therapies, but in our country, specialists still have to demonstrate at the institutions the treatment’s efficacy and cost-effectiveness for new insulin analogues. The aims of our study is to evaluate the efficacy of analogues vs human insulins and differences between various analogue insulin, in type 2 diabetes patients, previously treated with human insulin.
Methods: This study is realised in real life patients. We retrospectively included 384 patients, previously treated ≥24 months with human insulins, switched to an analogue insulin for ≥12 months. Treatment efficacy was evaluated by HbA1c levels, weight difference and changes in total daily dose (TDD) analogue vs human.
Results: 384 patients, 185 (48.17%) males. Glargine 194 (50.5%), detemir 110 (28.65%), and all other analogs (AOA) 80 (20.85%). Mean age 62.19 (S.D. 10.12) years, mean diabetes duration 10.8 (S.D. 5.35) years. Mean duration on analogue insulin therapy was 19.1 months. Overall mean HbA1c was 8.86 (S.D. 1.06) vs 7.51 (S.D. 1.51) on analogues P<0.01. TDD was 54.9 UI (S.D. 20.1) vs 62.56 UI (S.D. 27.95) on analogues P<0.05, but smaller basal doses 29.28 UI vs 28.1 UI. 21% of the patients on human insulin had an HbA1c <7% vs 63.1% on analogues. Patients on analogues had a slight weight increase +3.18 kg during the study period (P 0.55), but DE/GL 1.48 kg vs 4.14 kg (P<0.01).
Conclusions: A better metabolic control was noted with analogue vs human insulins, with smaller daily doses of basal insulin and minimal weight increase. Even in our study detemir group had a smaller weight gain, making it preferable for obese type 2 diabetics.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more